Scientists Re-Analyze old samples to unlock secrets of HER2-Low breast cancer
NCT ID NCT07561346
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This study looked at tissue samples from 2751 early breast cancer patients who had already completed chemotherapy. Researchers wanted to see if tumors with low levels of HER2 protein are biologically different from those with no HER2 at all. They used genetic testing and protein analysis to compare the two groups. The goal is to better understand these cancers and guide future treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hellenic Cooperative Oncology Group (HeCOG)
Athens, 11526, Greece
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a diabetes drug slow breast cancer growth?
- Young breast cancer patients share views on fertility risks in new survey
- Older women with Low-Risk breast cancer may avoid unnecessary surgery
- Could a pill replace chemo for some breast cancer patients?
- New daily pill could help breast cancer patients who Can't tolerate standard hormone drugs
- Immune cell clues in breast cancer tumors may predict Long-Term survival